Announcements Trials
Browse Landscape

Phase

Phase 4 6Phase NA 5Phase 2 3Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 1

Conditions

Smoking Cessation 1Neoplasms, Second Primary 1Cigarette Smoking 1Chemotherapy-Related Cognitive Impairment 1Breast Neoplasms 1Behavior, Addictive 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 280Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Completed × Tobacco Use Cessation Devices × Clear all
NCT04634071 2026-02-02

TTOP

University of Kentucky

Phase 2 Completed
126 enrolled

Smoking Cessation, Neoplasms, Second Primary, Behavior, Addictive

NCT05253573 2024-08-28

SurvLaos

University of Oklahoma

Phase 2 Completed
80 enrolled 15 charts

Cigarette Smoking

NCT02312934 2020-01-21

Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study

Vanderbilt University Medical Center

Phase 2 Completed
22 enrolled 14 charts
Breast

Chemotherapy-Related Cognitive Impairment, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡